The Role of the 21-Gene Recurrence Score® Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience
M Yordanova, S Hassan - Current Oncology, 2022 - mdpi.com
The management of patients with hormone receptor-positive breast cancer has changed
dramatically with use of the 21-gene Recurrence Score®(RS) Assay. While the utility of the …
dramatically with use of the 21-gene Recurrence Score®(RS) Assay. While the utility of the …
Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer
M Beniey, A Hubert, T Haque, AK Cotte… - British Journal of …, 2023 - nature.com
Background Patients with triple-negative breast cancer (TNBC) develop early recurrence.
While PARP inhibitors (PARPi) have demonstrated potential in BRCA1/2-mutant …
While PARP inhibitors (PARPi) have demonstrated potential in BRCA1/2-mutant …